Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced Dr. Ram Subramanian will join the company as a scientific advisor for their cannabinoid-based therapeutics targeting liver diseases.
As quoted in the press release:
“I am pleased that Dr. Subramanian has joined Revive to assist with advancing the research and clinical development of our cannabinoid-based research initiatives targeting liver diseases,” said Craig Leon, Chief Executive Officer of Revive. “Dr. Subramanian will be instrumental in guiding our research and clinical development initiatives in the field of liver disease.”
“I look forward to working with Revive in their objective of advancing novel cannabinoid-based therapeutic opportunities that address the unmet medical needs in liver diseases,” said Dr. Ram Subramanian.